Wearable Cardioverter-Defibrillator Use and Management

Introduction to Life Vest

• The American College of Cardiology reports that the wearable cardioverter-defibrillator (WCD) or "life vest" is a highly effective temporary protection device for individuals at risk of sudden cardiac death, with studies showing 99% first shock efficacy and 90% post-shock survival 1, 2
• A life vest is a vest-like device worn under clothing that continuously monitors heart rhythm and automatically delivers an electric shock when ventricular fibrillation (VF) or ventricular tachycardia (VT) is detected 2
• The device is designed to be worn continuously, 24 hours per day, except during bathing or showering 2
• The FDA has approved the device for patients who are "at risk for sudden cardiac arrest and are not candidates for or refuse an implantable defibrillator" 2

Indications for Life Vest Use

• The American College of Cardiology strongly recommends (Class IIa) the use of a life vest for patients with an ICD and history of sudden cardiac arrest or sustained ventricular arrhythmia requiring temporary ICD removal (e.g., due to infection) 2, 3
• This allows hospital discharge with protection until clinical situation permits ICD reimplantation 1
• The American College of Cardiology considers it reasonable (Class IIb) to use a life vest for patients awaiting cardiac transplantation 2
• The American College of Cardiology considers it reasonable (Class IIb) to use a life vest for patients with left ventricular ejection fraction ≤35% within 40 days after myocardial infarction 2
• The American College of Cardiology considers it reasonable (Class IIb) to use a life vest for patients with newly diagnosed non-ischemic cardiomyopathy with LVEF ≤35% before reassessment 2
• The American College of Cardiology considers it reasonable (Class IIb) to use a life vest for patients after recent revascularization (within 90 days) 2
• The American College of Cardiology considers it reasonable (Class IIb) to use a life vest for patients with myocarditis or secondary cardiomyopathy 2
• The American College of Cardiology considers it reasonable (Class IIb) to use a life vest for patients with systemic infection preventing immediate ICD implantation 2

Effectiveness and Outcomes

• Among 3,569 patients using the device, 80 VT/VF events occurred in 59 patients (1.7% per patient-year) 1
• First shock efficacy is remarkably high at 99% 1
• Post-shock survival rate is approximately 90% 1
• Overall inappropriate shock rate is approximately 2% 1
• A life vest may serve as a bridge to transplant even in patients with anticipated survival <1 year without transplant 1
• For patients after non-ST-elevation acute coronary syndromes with significantly reduced left ventricular ejection fraction, a life vest may be considered while awaiting reassessment for permanent ICD placement (typically at ≥40 days post-discharge) 4, 5

Management of Ventricular Fibrillation in Patients Wearing a LifeVest

Initial Response and Device Function

• The American College of Cardiology recommends allowing the LifeVest to issue alerts to the patient and bystanders, and to deliver a shock automatically if the patient becomes unresponsive, as part of its intended function to detect and treat ventricular fibrillation 6
• The device is designed to detect ventricular fibrillation and deliver an electric shock, and its use is supported by guidelines from the American College of Cardiology and the American Heart Association, as seen in the management of patients with ventricular fibrillation 6

Management Algorithm During VF Event

• If the LifeVest is delivering therapy, the American Heart Association recommends allowing the device to complete its shock delivery cycle, and not touching the patient during shock delivery to prevent injury to rescuers 6
• After shock delivery, the American Heart Association suggests assessing the patient's response and rhythm, as part of the post-shock management protocol 7
• If the LifeVest fails to deliver therapy or is not functioning, the American Heart Association recommends immediately beginning CPR with chest compressions, applying an external defibrillator as soon as available, and delivering a single shock (200J for biphasic defibrillator or 360J for monophasic) 7

Post-Shock Management

• After successful defibrillation, the American Heart Association recommends monitoring the patient closely for recurrence of VF, assessing vital signs and level of consciousness, and providing supportive care and arranging urgent cardiology consultation if necessary 7, 8
• For responsive patients, the American College of Cardiology suggests providing supportive care and arranging urgent cardiology consultation, and considering administering antiarrhythmic medication if indicated 6, 7

Special Considerations

• The American College of Cardiology notes that the LifeVest may deliver inappropriate shocks in some situations, and that inappropriate shocks can be caused by various factors such as atrial fibrillation, supraventricular tachycardia, motion artifacts, and oversensing of electrical signals, although this information is not directly cited 6
• However, it is recommended to avoid attempting to remove the LifeVest during an active VF event, and to avoid delaying external defibrillation if the LifeVest fails to deliver therapy, as per guidelines from the American College of Cardiology and the American Heart Association 6, 7

Medical Necessity of Wearable Defibrillators for Newly Diagnosed Dilated Cardiomyopathy

Rationale for Medical Necessity

• The American Heart Association and American College of Cardiology recommend allowing ≥6 months of optimal medical therapy in patients with newly diagnosed cardiomyopathy to allow for possible myocardial recovery when considering permanent ICD placement, with the wearable defibrillator serving as a bridge during this assessment period 9, 10
• Patients with newly diagnosed non-ischemic cardiomyopathy and LVEF <35% face substantial risk of sudden cardiac death, particularly in the first 90 days before medical therapy achieves maximal effect, making temporary protection with a wearable defibrillator necessary 11, 12

Standard 90-Day Reassessment Period

• Initiation of appropriate heart failure medications, such as beta-blockers, ACE-inhibitors/ARBs, and aldosterone antagonists, is a crucial step in managing patients with newly diagnosed dilated cardiomyopathy, as demonstrated by the patient's treatment with metoprolol succinate, aldactone, and losartan 13
• Cardiac catheterization is performed to rule out ischemic etiology in patients with newly diagnosed cardiomyopathy, as seen in this patient's case 14

Evidence Supporting Temporary Protection Strategy

• Guidelines from the American College of Cardiology support the use of a wearable cardioverter-defibrillator for patients with newly diagnosed non-ischemic cardiomyopathy with LVEF ≤35% before reassessment, as a Class IIb recommendation 11, 12

Clinical Algorithm

• The American College of Cardiology recommends a step-wise approach to managing patients with newly diagnosed dilated cardiomyopathy, including confirmation of diagnosis, exclusion of reversible causes, initiation of optimal medical therapy, and reassessment of LVEF at 60-90 days, with permanent ICD implantation considered if LVEF remains ≤35% after 90 days 13, 15

Wearable Cardioverter‑Defibrillator (WCD) Recommendations for Early Systolic Heart Failure

Primary Indications (Class IIb – Reasonable to Consider)

• The American College of Cardiology (ACC) deems WCD use reasonable for patients ≤40 days after myocardial infarction (MI) with a left‑ventricular ejection fraction (LVEF) ≤ 35 % as a temporary bridge to definitive ICD therapy. 16
• The ACC also considers WCD reasonable for patients awaiting cardiac transplantation who cannot receive an immediate ICD because of temporary contraindications. 17

Evidence Quality and Knowledge Gaps

• The 2014 ACC/AHA/HRS consensus statement notes that data supporting WCD use as a bridge therapy are scant, reflecting limited high‑quality evidence. (Class IIb, Level C) 16
• Large pivotal trials (SCD‑HeFT, MADIT‑II) excluded patients within 40 days post‑MI and demonstrated no survival benefit until at least one year of follow‑up, underscoring the uncertainty of early WCD benefit. 17

Decision Algorithm: Timing Relative to MI

• If < 40 days post‑MI and LVEF ≤ 35 %, a permanent ICD is contraindicated; WCD may be used as temporary protection. (ACC recommendation, Class IIb) [16][17]18
• If ≥ 40 days post‑MI with LVEF ≤ 30 % and NYHA class I, a permanent ICD is recommended rather than a WCD. (ACC recommendation, Class IIa) 18

Optimizing Guideline‑Directed Medical Therapy (GDMT) Before Device Decisions

• The 2022 AHA/ACC/HFSA guidelines stress that maximizing GDMT (including ACE‑I/ARB, beta‑blocker, SGLT2‑inhibitor, and mineralocorticoid receptor antagonist therapy) should precede any device implantation decision. (Class I, Level A) 18
• ACE‑I or ARB therapy is indicated for patients with LVEF ≤ 40 % as part of GDMT. (AHA/ACC, Class I) 18
• Evidence‑based beta‑blockers are also recommended for the same population. (AHA/ACC, Class I) 18

When Permanent ICD Is Preferred Over WCD

• Patients ≥ 40 days post‑MI with persistent LVEF ≤ 30 % despite optimal GDMT should be evaluated for permanent ICD implantation rather than continued WCD use. (AHA/ACC, Class IIa) 18
• If revascularization is unlikely to improve LVEF > 35 % and the patient is beyond the 40‑day post‑MI window, a permanent ICD is preferred. (ACC, Class IIa) 16

Contraindications and Patient‑Selection Considerations

• Do not use WCD in patients listed for heart transplantation or with a left ventricular assist device (LVAD) within 40 days of MI, as no benefit has been demonstrated. (ACC, Class III) [16][17]
• Do not use WCD in patients with NYHA Class IV heart failure, where sudden cardiac death is less likely to be arrhythmic. (ACC, Class III) 16

Common Clinical Pitfalls

• Using the WCD as a substitute for optimizing GDMT is discouraged; GDMT remains the primary intervention. (AHA/ACC, Class IIb) 18
• Implanting a permanent ICD within 40 days post‑MI solely based on low LVEF is not recommended because survival benefit is not evident until after one year and LVEF may improve with therapy. (ACC, Class III) [16][17]18

Historical Guideline Perspective

• The 2005 European Society of Cardiology (ESC) guidelines classified external ventricular assist devices, including WCDs, as Class IIb with Level C evidence, reflecting limited data at that time. (ESC, Class IIb, Level C) 19